[A new therapeutic possibility for type 2 diabetes: DPP-4 inhibitors (sitagliptin)]
Author(s): Abel T, Feher J
Affiliation(s): Allami Egeszsegugyi Kozpont, Szakrendelo Intezet, Budapest. drabelt@t-online.hu
Publication date & source: 2010-06-20, Orv Hetil., 151(25):1012-6.
Publication type: English Abstract; Review
Type 2 diabetes is a very common worldwide disorder. A good glycemic control is reduce the rates of diabetes associated microvascular and possibly macrovascular complications. Dipeptidyl peptidase-4 (DPP-4) inhibitors such as sitagliptin demonstrate an incretin based, glucose-dependent actions with low risk of hypoglycemia and no weight gain during the treatment of patients with type 2 diabetes.
|